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Background: Although hypertension is a major risk factor for cardiovascular disease, adherence 
to hypertensive medications is low. Previous research identifying factors influencing adherence 
has focused primarily on broad, population-based approaches. Identifying specific barriers for 
an individual is more useful in designing meaningful targeted interventions. Using customized 
telephonic outreach, we examined specific patient-reported barriers influencing hypertensive 
patients’ nonadherence to medication in order to identify targeted interventions.
Methods: A telephone survey of 8692 nonadherent hypertensive patients was conducted. The 
patient sample comprised health plan members with at least two prescriptions for antihypertensive 
medications in 2008. The telephone script was based on the “target” drug associated with 
  greatest nonadherence (medication possession ratio [MPR] ,80%) during the four-month 
period preceding the survey.
Results: The response rate was 28.2% of the total sample, representing 63.8% of commercial 
members and 37.2% of Medicare members. Mean age was 63.4 years. Mean MPR was 61.0% 
for the target drug. Only 58.2% of Medicare respondents and 60.4% of commercial respon-
dents reported “missing a dose of medication”. The primary reason given was “forgetfulness” 
(61.8% Medicare, 60.8% commercial), followed by “being too busy” (2.7% Medicare, 18.5% 
commercial) and “other reasons” (21.9% Medicare, 8.1% commercial) including travel, 
hospitalization/  sickness, disruption of daily events, and inability to get to the pharmacy. Pre-
scription copay was a barrier for less than 5% of surveyed patients.
Conclusion: Our findings indicate that events interfering with daily routine had a significant 
impact on adherence. Medication adherence appears to be a patterned behavior established 
through the creation of a routine and a reminder system for taking the medication. Providers 
should assess patients’ daily schedules and medication-taking competency to develop and 
promote a medication routine.
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Background
Hypertension is a major risk factor for cardiovascular disease. Although antihypertensive 
medications have been demonstrated to control hypertension, over half of patients 
stop taking their medications entirely within a year of diagnosis, and only 31% take 
at least 80% of their prescribed medication.1,2 A World Health Organization report3 
estimates that adherence to antihypertensive medications ranges from 52% to 74% 
when adherence is defined as possession of a medication at least 80% of the time.4,5 
This World Health Organization report identified nonadherence to medical   treatment 
as a major public health concern, especially in patients with chronic conditions 
(eg, hypertension).3Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Medication adherence is defined as the extent to which 
a patient follows a given therapeutic medication regimen as 
agreed on in partnership with a health care professional.3 
In the context of hypertension, medication adherence has been 
associated with improved health outcomes.6 Mazzaglia et al7 
demonstrated that, in 18,806 newly diagnosed hypertensive 
patients, those with high medication adherence (considered 
to be 80% of the days covered with drug therapy) had 38% 
fewer acute cardiovascular events long term compared with 
patients with low medication adherence. The literature on 
medication adherence has led to the development of several 
classifications of factors that influence nonadherence. Over 
250 factors have been identified, including patient abilities, 
beliefs, involvement, practical difficulties, support systems, 
and provider relationships.8
Kingsnorth and Wilkinson9 described medication 
nonadherence as having two components, ie, a purposeful 
decision-making process wherein patients intentionally 
choose to stop taking their medication due to beliefs or 
perceptions about the medication, and a random departure 
from taking medication due to factors such as forgetfulness, 
interruption of daily routines, inability to access medications, 
or lack of reminders. Therefore, medication nonadherence has 
been reconceptualized as either intentional or unintentional.10 
This reconceptualization has allowed researchers to 
expand their focus beyond patient perceptions of medication-
taking to include patients’ actual abilities to carry out 
medication treatment plans.
Harmon et al11 categorized barriers for nonadherence 
among hypertensive patients as intentional nonadherence 
barriers, which include knowledge or perceptions of 
the disease, cost, complexity of antihypertensive regimens, 
side effects, and unintentional nonadherence barriers, which 
include forgetfulness and lack of access to medications. 
Research examining these barriers has shown that intentional 
nonadherence is based on a misunderstanding of the 
condition (ie, the patient “assumed blood pressure was 
normal”), side effects, asymptomatic nature of the disease, 
cost of medication, complexity of regimen (“concern about 
having too many medications”), and switching to a generic 
medication.12,13 (Although switching to less costly generic 
medications could actually improve adherence, in some 
cases, switching to a generic drug could lead to a real or 
perceived increase in side effects or a decrease in efficacy 
which, in turn, could lead to nonadherence). Unintentional 
barriers are based on forgetfulness (“forgetting to take the 
medication when the usual routine changes”), availability 
of transportation to the pharmacy, and having to obtain 
medications every month.13
The primary goal of this study was to conduct a deeper 
examination of which patient-identified barriers influence 
adherence for a large sample of commercially-insured and 
Medicare-insured hypertensive patients, using telephone 
surveys. Secondary objectives were to determine the 
distribution of respondents who were taking the various 
classes of antihypertensive medications, and to compare 
patient characteristics between commercially-insured and 
Medicare-insured patients in order to determine whether 
there were any differences in adherence patterns between 
those younger and older than 65 years of age and whether 
type of insurance influenced adherence.
Methods
Design
A telephone survey of 8692 nonadherent hypertensive 
patients was conducted to identify whether their nonad-
herence was intentional, unintentional, or a combination 
of both. Patients were identified using pharmacy claims 
data from a large health insurance plan in the mid-Atlantic 
US that included commercial (,65 years) and Medicare 
members ($65 years). Criteria for participation included 
age $18 years, at least two consecutive prescription fills 
for an antihypertensive medication between January 1, 
2008 and August 31, 2008, from the drug classes of alpha-
blockers, beta-blockers, calcium channel blockers, diuretics 
(excluding furosemide), angiotensin receptor blockers, 
angiotensin-  converting enzyme inhibitors, antihypertensive 
combinations, antiadrenergic antihypertensives, and direct 
renin inhibitors, and enrollment in the health plan at the time 
of the survey.
From this group, patients with a medication possession 
ratio (MPR) of ,80% for at least one of their antihypertensive 
medications, as determined from pharmacy claims data, 
were chosen. This MPR was selected because, first, it is a 
commonly used benchmark of nonadherence,4,5 and second, 
an MPR of ,80% has been associated with increased 
hospitalizations.14 If patients were taking more than one 
antihypertensive medication, the drug with the lowest MPR 
in the four-month period preceding the survey was used as the 
“target” drug to assess whether they could be included in the 
study sample. If individuals had an MPR , 80% for more 
than one antihypertensive medication, the one with the most 
recent use as identified by the last fill date was designated as 
the target medication.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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A pilot test of the telephone survey was conducted in the 
summer of 2008 using a subset of 500 patients. The telephone 
survey was implemented between October and December 
2008 by Care Management International.15 Three attempts 
were made to contact patients who were nonadherent or their 
dependents (who were permitted to serve as health proxies), 
and an incoming call line was established for plan members 
or dependents who wanted to return calls. Calls were made by 
trained employees of Care Management International using a 
pilot-tested and validated script that directed respondents to 
specific follow-up questions about barriers to adherence based 
on their individual responses to key domain questions. The 
pilot test revealed that some survey items and skip   patterns of 
questions needed to be modified. Accordingly, a revised script 
was utilized on members of the pilot sample (n = 500) who 
did not complete the pilot survey in the first round (ie, they 
could not be reached or they did not have time to complete 
the survey). Based on the results of the pilot survey, the 
survey items were modified to create a final pilot-tested and 
validated survey. The telephone survey averaged eight minutes. 
Institutional Review Board (IRB) approval was obtained, and 
patients’ responses to the survey were used as a proxy (per 
IRB process) for implied and informed consent.
Key survey items
We examined eight domains, ie, confirmation that the 
respondent had hypertension and was using the target drug, 
dosing pattern of the target medication, means of purchase 
of the medication, self-reported nonadherence, barriers to 
nonadherence, self-reported aids to overcome nonadherence, 
use of mail-order pharmacy services, and preferred method 
of receiving educational materials. Follow-up questions 
were tailored to an individual’s response to the key domain 
question. Selected survey items used to measure key domains 
and a sampling of follow-up questions are described in the 
Appendix.
Other measures
Demographic measures
Age, gender, and primary subscriber to the health plan 
(patient or other) as of 2008 were determined for respon-
dents and nonrespondents, as determined from claims 
(enrollment) data.
clinical measures
The Prescription Drug Hierarchical Condition Category 
(RxHCC) score was determined for each individual in 2008. 
This risk score was developed by Centers for Medicare and 
Medicaid Services for Medicare Part D beneficiaries using 
data from the Federal Employee Health Plan run by Blue 
Cross Blue Shield.16 The risk score uses diagnosis codes in a 
base year to predict an individual’s prescription costs for the 
following year. The RxHCC   diagnostic classification system 
categorizes more than 15,000 International Classification of 
Diseases, Ninth Revision (ICD-9) diagnosis codes into 197 
conditions or RxHCCs, and uses these categories in the model, 
where cost denotes total prescription expenditures and is the 
outcome variable. Explanatory variables include 24 mutu-
ally exclusive age/gender categories, disabled status, and the 
RxHCCs, which are a vector of diagnostic categories.
Medication use and adherence
This was determined from pharmacy claims as the total 
number of antihypertensive medications (including the 
target medication) an individual was taking, total number 
of all medications (including antihypertensive medications) 
an individual was taking, adherence rate of the target 
  medication (as identified by MPR $80%), adherence rate 
for other antihypertensive medications excluding the target 
medication, and nonadherence strata in which respondents 
were categorized, ie, 0%–19%, 20%–39%, 40%–59%, and 
60%–79%.
comorbidities
Presence of comorbidities in 2008 was determined on 
the basis of patients’ self-reported diagnoses during the 
telephone conversation, and comprised diabetes, depression, 
dyslipidemia, chronic kidney disease, congestive heart 
failure, coronary heart disease, and ischemic stroke.
statistical analysis
Univariate descriptive analysis was used to compare respon-
dents and nonrespondents on demographic characteristics 
(n [%]), clinical characteristics (mean ± standard deviation 
[SD]), medication use and adherence (mean ± SD and n [%]), 
presence of specific comorbidities (n [%]), medical utiliza-
tion (mean ± SD), and expenditures (mean ± SD). A similar 
analysis was used to compare the commercially-insured 
and Medicare-insured respondents. Univariate analysis was 
also used to describe differences between commercially-
insured and Medicare-insured enrollees’ responses regarding 
“confirming hypertension and use of target drug”, “dosing 
pattern of target drug”, “source of medication purchase”, 
“self-reported nonadherence”, “use of mail-order pharmacy Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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services”, and “preferred method of receiving educational 
materials”.   Differences in specific barriers to adherence 
and self-reported aids to overcoming adherence between 
these two groups were assessed, adjusting for age and 
gender using odds ratios with associated 95% confidence 
intervals; P   values were reported (P , 0.5 denotes statisti-
cal significance). All analyses were conducted using SAS 
version 9.2.
Results
response rates
A total of 8692 members were eligible to participate in the 
study. Of those, 2383 (27.4%) members completed the entire 
telephone survey, and another 68 (,1.0%) responded to 
part of the telephone survey. Thus, the overall response rate 
was 28.2% (n = 2451), representing 63.8% of commercial 
members and 37.2% of Medicare members.
respondents versus nonrespondents
Respondents (n = 2451) were older (63.4 years versus 
58.6 years), had a greater percentage of females (54.3% 
versus 47.3%), and had higher RxHCC risk scores (1.143 
  versus 1.096) compared with nonrespondents (n = 6241, see 
Table 1). Adherence rates for the target drug were similar for 
both groups at approximately 60%, as was adherence to other 
antihypertensive medications (approximately 85%).
commercially-insured versus  
Medicare-insured respondents
As shown in Table 2, Medicare-insured respondents (n = 887) 
were older (75.5 years versus 56.4 years), had a greater per-
centage of females (64.3% versus 48.7%), and had higher 
RxHCC risk scores (1.167 versus 1.129) compared with 
commercially-insured respondents (n = 1564). Medicare-
insured respondents also had a slightly higher number of 
antihypertensive medications (2.9 versus 2.4) and total 
number of medications (11.2 versus 10.2). Adherence rates 
for the target drug were slightly higher for commercially-
insured respondents (61.1% versus 59.9%), while adherence 
to other antihypertensive medications was slightly higher for 
Medicare-insured respondents (87.4% versus 84.5%) among 
those taking multiple antihypertensive medications. Medicare-
insured respondents had higher rates of all comorbidities 
examined, notably coronary heart disease (23.8% versus 
10.5%), congestive heart failure (15.3% versus 6.1%), chronic 
kidney disease (8.9% versus 4.1%), dyslipidemia (19.5% 
versus 13.5%), and diabetes (19.3% versus 12.3%).
Distribution of drug classes and 
adherence strata for target drugs
Among the target drugs, beta-blockers represented 32% of 
those targeted for commercially-insured respondents and 
Table 1 comparing characteristics of survey respondents with those of nonrespondents
Respondents Nonrespondents P value
sample size, n 2451 6241
Demographics
Age, mean (sD) 63.4 (13.68) 58.6 (13.45) ,0.0001
Females, n (%) 1332 (54.3%) 2950 (47.3%) ,0.00001
Primary subscribers, n (%) 2061 (84.1%) 4985 (79.9%) ,0.0001
Risk score
rxhcc score, mean (sD) 1.143 (0.3212) 1.096 (0.3143) ,0.0001
Medication use and adherence
Number of all antihypertensive medications, mean (sD) 2.6 (1.50) 2.3 (1.40) ,0.0001
Number of all medications including antihypertensive  
medications, mean (sD)
10.6 (6.38) 9.6 (6.31) ,0.0001
Adherence to target medication, mean (sD) 60.7 (13.94) 60.5 (14.11) 0.6432
Adherence to all other antihypertensive medications except  
the target medication, mean (sD)
85.6 (17.11) 84.2 (17.53) 0.0026
Comorbidities
Members with diabetes, n (%) 363 (14.8%) 784 (12.6%) ,0.0001
Members with depression, n (%) 69 (2.8%) 197 (3.2%) 0.4057
Members with dyslipidemia, n (%) 384 (15.7%) 838 (13.4%) 0.0069
Members with chronic kidney disease, n (%) 143 (5.8%) 254 (4.1%) 0.0004
Members with congestive heart failure, n (%) 232 (9.5%) 407 (6.5%) ,0.0001
Members with coronary heart disease, n (%) 376 (15.3%) 793 (12.7%) 0.0012
Members with ischemic stroke, n (%) 50 (2.0%) 118 (1.9%) 0.6492
Abbreviations: sD, standard deviation; rxhcc, Prescription Drug hierarchical condition category.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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24% of those targeted for Medicare-insured respondents 
(Figure 1). Diuretics represented the target drug for 21.4% 
of commercial and 18.1% of Medicare respondents, followed 
by angiotensin-converting enzyme inhibitors (18.2% 
  commercial and 15.9% Medicare), and angiotensin receptor 
blockers (13.1% commercial versus 15.9% Medicare). None 
of the respondents were taking calcium channel blockers as 
the target drug.
A majority of respondents in both groups (58.6% 
  Medicare and 60% commercial) had adherence rates between 
60% and 79% for their target drug. About a third of respon-
dents in each group had adherence rates between 40% and 
59% for their target drug.
Key survey domain responses
Confirming hypertension and use of target drugs
More than three quarters of both Medicare-insured (78.7%) 
and commercially-insured (82.4%) respondents confirmed 
that they were using the target drug for hypertension. About 
12% of the Medicare group and 8% of the commercial group 
reported not taking the target drug, but were taking an alterna-
tive drug to manage their hypertension, while ,5% in each 
group reported not taking their target drug anymore. Over 
96% of all respondents claimed that their blood pressure 
was under control.
Dosing pattern of target drug
A majority of respondents in both groups (72.2% commercial 
and 80.32% Medicare) took their target drug once a day. 
Between 17% and 24% of each group reported taking their 
target medication twice a day, while ,5% reported taking it 
three times a day or had some other dosing schedule. Over 
66% of each group reported taking their medication in the 
morning, 6% said they took it in the afternoon, and 28% said 
they took it in the evening.
self-reported nonadherence
There were 58.2% Medicare-insured and 60.4% commercially-
insured respondents who reported missing a dose of their 
target medication (P = 0.2892). For those who reported not 
missing a dose of their medication, 13.1% of the Medicare-
insured group and 16.3% of the commercially-insured group 
did report picking up their prescriptions a few days after 
running out of pills (P = 0.1822).
Barriers to adherence
The primary self-reported barrier to adherence appeared to 
be forgetfulness (64.9% Medicare and 73.32% commercial, 
P = 0.0320, Table 3). A closer examination of why respon-
dents forgot to take their medication revealed that 23.3% 
of commercially-insured and 12.9% of Medicare-insured 
Table 2 comparing characteristics of commercially-insured survey respondents with those of Medicare-insured respondents
Commercially-insured 
respondents
Medicare-insured 
respondents
P value
sample size, n 1564 887
Demographics
Age, mean (sD) 56.4 (10.84) 75.7 (8.50) ,0.0001
Females, n (%) 762 (48.7%) 570 (64.3%) ,0.0001
Primary subscribers, n (%) 1174 (75.1%) 887 (100%) ,0.0001
Risk score
rxhcc score, mean (sD) 1.129 (0.3178) 1.167 (0.3260) 0.0046
Medication use and adherence
Number of all antihypertensive medications, mean (sD) 2.4 (1.45) 2.9 (1.52) ,0.0001
Number of all medications including antihypertensive  
medications, mean (sD)
10.2 (6.61) 11.2 (5.92) 0.0007
Adherence to target medication, mean (sD) 61.1 (13.80) 59.9 (14.17) 0.0424
Adherence to all other antihypertensive medications 
except the target medication, mean (sD)
84.5 (17.69) 87.4 (16.05) 0.0004
Comorbidities
Members with diabetes, n (%) 192 (12.3%) 171 (19.3%) ,0.0001
Members with depression, n (%) 41 (2.6%) 28 (3.2%) 0.4414
Members with dyslipidemia, n (%) 211 (13.5%) 173 (19.5%) ,0.0001
Members with chronic kidney disease, n (%) 64 (4.1%) 79 (8.9%) ,0.0001
Members with congestive heart failure, n (%) 96 (6.1%) 136 (15.3%) ,0.0001
Members with coronary heart disease, n (%) 165 (10.5%) 211 (23.8%) ,0.0001
Members with ischemic stroke, n (%) 18 (1.2%) 32 (3.6%) ,0.0001
Abbreviations: rxhcc, Prescription Drug hierarchical condition category; sD, standard deviation.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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respondents were “too busy sometimes” (P = 0.0002), 
6.6% of commercially-insured and 4.1% of Medicare-
insured respondents were “traveling and forgot to pack 
their medication” (P = 0.0939), and ,2% of each group 
reported they were not able to perform their daily routine 
(P = 0.3628).
Copays were a barrier for ,5% of each group (P = 0.0273, 
Table 4). Medicare members were 7.60 times more likely to 
report not being able to make it to the pharmacy as compared 
with commercial enrollees. Medicare members were also 
1.62 times more likely to report “other reasons” as a barrier 
as compared with commercial respondents. Because “other 
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Figure 1 Distribution of respondents in the antihypertensive drug classes for Medicare-insured and commercially insured respondents.
Notes: *represents drug class of target drug. Diuretics drug class excludes those taking only furosemide for hypertension.
Table 3 Barriers to adherence for Medicare-insured and commercially-insured survey respondents
  Medicare-insured 
respondents 
(n = 490)
Commercially- 
insured respondents 
(n = 907)
Adjusted 
OR
95% CI P value
n % n %
copay was too high 25 5.1 32 3.53 2.407 1.103 5.249 0.1582
Drug had too many side effects 3 0.61 8 0.88 0.473 0.076 2.622 0.5886
Drug was not effective 0 0 1 0.11 NA      0.9505
i just forgot 318 64.9 665 73.32 0.69 0.491 0.853 0.001
Blood pressure is under control  
without medication
12 2.45 10 1.1 1.457 0.432 5.25 0.0602
Blood pressure is under control  
with other things
0 0 4 0.44 NA  NA    NA 
Too busy 13 2.65 168 18.52 0.168 0.087 0.326 ,0.0001
could not make it to pharmacy 31 6.33 8 0.88 7.59 3.461 16.645 ,0.0001
Other reason 113 23.06 79 8.71 1.618 1.032 2.535 ,0.0358
Notes: *reference group comprises commercial respondents and is adjusted for age and gender. survey question: “can you tell me a little bit about why you missed 
your dose of [target drug] that time?” (Note that only 60% of nonadherent patients reported missing a dose, suggesting that 40% were unaware of their nonadherence). 
Sample size for each question represents those members who responded to the specific question they were directed to, and therefore can vary from question to question. 
Abbreviations: NA, sample size too small to conduct adjusted analysis; OR, odds ratio; CI, confidence interval.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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reasons” represented between 8% and 23% of all responses 
in each group, a qualitative examination of the other category 
(Figure 2) revealed that the predominant reason for missing a 
medication dose was disruption in daily routine, including a 
change of routine on weekends or on vacation, or unintended 
behaviors, such as falling asleep or being late for work.
self-reported aids to overcoming 
nonadherence
Approximately 50% of respondents in each group reported 
“part of their daily routine” as helping them remember to take 
their target medication (P = 0.1181). About 25% of members 
in each group reported they were “good about remembering” 
to take their medication (P = 0.5009).   Medicare members 
were 2.02 times more likely to report having family or 
friends’ support to help remind them about taking their 
target medication as compared with commercially-insured 
respondents. Over 70% cited other reasons, such as using a 
pill box, while 14% reported keeping medications in a visible 
place as a reminder aid.
Means of medication purchase
A majority of respondents in each group (73.5% commercial 
and 57.7% Medicare) purchased their target medication 
through the pharmacy benefit of their health plan. Between 
11.6% and 15.5% said they receive their target drug directly 
Table 4 self-reported aids to overcoming adherence for Medicare-insured and commercially-insured survey respondents
Medicare-insured 
respondents 
(n = 301)
Commercially-  
insured respondents 
(n = 490)
Adjusted  
OR
95% CI P value
n % n %
has support of family or friends 27 8.97 22 4.49 1.293 0.584 2.86 0.526
sets a reminder 5 1.66 14 2.86 0.595 0.162 2.189 0.5351
Part of a daily routine 140 46.51 256 52.24 1.084 0.739 1.589 0.6807
Just good about remembering 68 22.59 121 24.69 0.624 0.397 0.98 0.0408
Other 61 20.27 77 15.71 1.474 0.894 2.431 0.1281
Notes: *reference group comprises commercial respondents and is adjusted for age and gender. survey question: “What helps you to remember to take your medication?” 
Sample size for each question represents those members who responded to the specific question they were directed to, and therefore can vary from question to question. 
Abbreviations: OR, odds ratio; CI, confidence interval.
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Figure 2 self-reported “other reasons” for nonadherence by Medicare-insured and commercially insured respondents.
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as samples from their physician (and therefore may have been 
considered nonadherent).
Use of mail-order pharmacy services
For respondents who reported they were late in picking up 
their prescription, 35.1% of Medicare-insured and 48.1% of 
commercially-insured respondents (P , 0.0001) reported 
that they would be interested in using mail-order pharmacy 
services to obtain their target medication.
Preferred method of receiving 
educational materials
A majority of respondents in both groups (62.4% commercial 
and 75.1% Medicare) preferred to receive educational 
material through regular mail. A higher percentage of 
commercially-insured respondents (15.1%) as compared 
with Medicare-insured respondents (3.8%) preferred to 
receive information via email. Approximately 12% of each 
group preferred to receive information through calls from a 
live agent, while ,2% wanted to receive calls through an 
automated response voice system.
Discussion
These data highlight several important issues. First, despite 
selecting a sample of hypertensive patients who had been 
determined to be nonadherent to at least one of their 
antihypertensive medications, our results indicate that only 
about 60% of respondents reported missing a dose of their 
medication, and an additional 15% reported picking up their 
pills a few days late. Thus, only 75% of the respondents 
reported nonadherence to the target drug. This is in line 
with the rate of underreporting cited in a study assessing the 
presence of discrepancies by comparing medication bottles 
with medication records,17 in which discrepancies between 
recorded and reported medication use were observed for 76% 
of the study population.
Second, differences in age did not appear to influence 
nonadherence, as suggested by the similar adherence rates 
for commercially-insured and Medicare-insured patients 
despite the significant age difference. Previous research has 
also shown that age does not predict adherence reliably.18
The most important finding is that unintentional 
nonadherence appears to be the primary form of nonadherence 
for the hypertensive patients in our study. A majority 
of respondents reported simply forgetting to take their 
medications if they were too busy or if they experienced 
disruptions in their daily routine, such as being late for 
work, traveling, vacationing, being sick or hospitalized, or 
undergoing medical tests that required them to discontinue 
their medications. More Medicare members reported access-
related issues of not being able to make it to the pharmacy 
compared with commercial members, while more commercial 
members reported missing a dose of their medication because 
they were too busy.
Previous adherence studies in hypertensive populations 
were based on the notion that medication-taking behavior 
depends on the value a patient places on a particular 
outcome (eg, the effects of uncontrolled hypertension) and 
the patient’s estimate of the likelihood that a particular 
activity (use of antihypertensive medications) will produce 
a desired outcome (controlling hypertension).19 We did not 
measure the value our study subjects placed on particular 
outcomes, nor did we assess their estimates of the likelihood 
that the use of antihypertensive medications would produce 
a desired outcome. Therefore, we cannot report any findings 
that confirm or refute the influence of patient values and 
expectations on medication adherence. Rather, our findings 
indicate that medication adherence appears to be a patterned 
behavior established through the creation of a routine and 
a reminder system for taking the medication. Disruption 
of this routine, due to external events and triggers, leads to 
nonadherence.
As a first step in designing meaningful interventions, 
health care providers can assess daily lifestyle and demands 
for hypertensive patients to determine the likelihood of 
disruption by asking simple questions such as, “Can you 
take your medications on a regular basis”? or “What is your 
routine in taking your medications”? The information from 
this assessment can help providers determine which dosing 
schedule (and thereby which medication) a patient is capable 
of being adherent to, along with potential times and locations 
to develop a regular pattern of taking medications.
Information about a patient’s lifestyle can be used to 
develop strategies to minimize unintentional nonadherence. 
Such strategies could include telephone or email reminders, 
or the use of medication charts that patients can refer to and 
check off each time they take their medication. In a review of 
interventions designed to improve adherence for cardiovascular 
medications, five randomized clinical trials which utilized 
prompting mechanisms such as daily and weekly telephone 
calls, video telephone calls, mailed reminders, and electronic 
medication reminder caps were examined.19 In three of 
these trials, prompting mechanisms significantly increased 
adherence compared with usual care.
Providers can also reinforce the importance of taking 
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about the necessity of these medications continue to be 
maintained and allow patients to make fewer unintentional 
decisions about taking their medications.
Our study had several limitations. First, we were not 
able to examine the impact of nonadherence on actual blood 
pressure readings. We did not have access to patient charts 
and so were unable to determine whether respondents who 
were nonadherent to their target medication were also unable 
to control their hypertension. As a proxy for this measure, 
one of the follow-up questions asked was, “Do you know 
if your blood pressure is under control”? Over 96% of all 
respondents responded affirmatively. However, without 
verifying this information with clinical data, we were not 
able to assess the clinical impact of nonadherence in our 
study sample.
Second, we decided to use only the antihypertensive 
medication associated with the lowest adherence rate in 
the telephone survey, irrespective of how many other 
antihypertensive medications respondents were taking. The 
choice of the primary hypertensive drug was based on the 
most recent hypertensive drug prescribed to a member in 
order to minimize recall bias among the respondents. Given 
the possibility that members may have switched between 
hypertensive drugs, which happens frequently for clinical 
reasons, we chose to focus on one recent and primary 
hypertensive drug to ensure that respondents would be able 
to recall as much detail as possible. Pharmacy claims revealed 
that, on average, respondents were taking 2.6 hypertensive 
medications, with a mean adherence rate of 85%. The 
overall adherence to other antihypertensive medications 
excluding the target drug was high for our study sample. 
Selecting a sample whose adherence rates were ,80% for 
all antihypertensive drugs may have been a better approach 
for identifying nonadherent hypertensive patients and could 
have yielded different results. Third, we did not survey 
hypertensive patients with high adherence ($80%) in order 
to compare their responses with those of patients with 
low or moderate adherence. This comparison would have 
provided a more complete picture of the barriers that affect 
nonadherence and should be undertaken in future studies.
Fourth, we present results of analyses that adjusted only 
for age and gender when comparing the group differences 
with regard to barriers to adherence and self-reported aids 
to overcoming nonadherence. We did conduct an adjusted 
analysis that controlled for a number of additional variables 
including age, gender, RxHCC risk score, adherence 
rate for target hypertensive medication, total number 
of antihypertensive medications, total number of all 
prescriptions, and member out-of-pocket expenditures for all 
medications, which were the variables available from claims 
data we felt could most likely explain some of the between-
group differences. More information about occupation, 
income, and education for the two groups of patients (under 
and over 65 years of age) would have allowed for more 
meaningful interpretation of the data.
Fifth, we used several skip patterns and follow-up nested 
questions in our telephone survey in order to understand the 
reasons why patients reported a specific barrier. The more 
involved study design resulted in small sample sizes for 
some of the follow-up questions, thus limiting our ability to 
conduct more detailed and multivariate analyses comparing 
the commercially-insured and Medicare-insured groups.
Sixth, the inclusion of an insured study population may 
not be representative of other patient groups. And finally, 
the lack of sampling of a comparison group with high MPR 
for the same target drugs diminishes the utility in identifying 
factors associated with nonadherence.
Conclusion
Our study findings have furthered our understanding of 
what drives nonadherence in hypertensive patients. Patients 
nonadherent to at least one hypertensive medication appeared 
to exhibit unintentional nonadherence. The primary reason 
for unintentional nonadherence was forgetfulness. Factors 
that triggered forgetfulness appeared to be a disruption 
in daily routine, such as a change in routine on weekends 
or on vacation, or other behaviors, such as falling asleep 
or being late for work. Other reasons included missing a 
medication dose due to sickness, hospitalization, or a medical 
procedure that required them to stop taking their medication. 
These findings can be used to design interventions that 
take into account patients’ daily lifestyles and to design 
medication treatment plans that cause the least disruption 
to the patient.
Disclosure
This study was funded by Novartis Pharmaceuticals 
Corporation. DAB and JJD are employees of Novartis 
Pharmaceuticals Corporation.
References
1.  Mapes RE. Physicians drug innovation and relinquishment. Soc Sci Med. 
1977;11:619–624.
2.  Sackett DL, Haynes RB, Gibson ES, et al. Randomized clinical trial of 
strategies for improving medication compliance in primary hypertension. 
Lancet. 1975;1:1205–1207.
3.  Sabate E. Adherence to long term therapies: Evidence for action. Geneva, 
Switzerland: World Health Organization; 2003.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
204
Nair et al
  4.  Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of 
medication adherence and persistence using automated databases. 
Pharmacoepidemiol Drug Saf. 2006;15:565–574.
  5.  Sikka R, Xia F, Aubert RE. Estimating medication persistency using 
administrative claims data. Am J Manag Care. 2005;11:449–457.
  6.  DiMatteo M, Giordani P, Lepper H, et al. Patient adherence and medical 
treatment outcomes. Med Care. 2002;40:794–811.
  7.  Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to 
antihypertensive medications and cardiovascular morbidity among newly 
diagnosed hypertensive patients. Circulation. 2009;120:1598–1605.
  8.  Cameron C. Patient compliance: Recognition of factors involved and 
suggestions for promoting compliance with therapeutic regimens.   
J Adv Nurs. 2007;24;244–250.
  9.  Kingsnorth D, Wilkinson S. Patient compliance with medication 
  regimens after discharge from palliative care. Int J Palliat Nurs. 1996;2: 
144–148.
  10.  Lehane E. An examination of intentional and unintentional aspects of 
medication non adherence in patients diagnosed with hypertension.   
J Clin Nurs. 2007;16:698–706.
  11.  Harmon G, Lefante J, Wood-Krousel M. Overcoming barriers: Role 
of providers in improving patient adherence to antihypertensive 
medications. Curr Opin Cardiol. 2006;21:310–315.
  12.  Staffan S, Kjellgren KI, Ahlner J, Saljo R. Reasons for adherence with 
antihypertensive medications. Int J Cardiol. 2000;76:157–163.
  13.  Turner BJ, Hollenbeak C, Weiner MG, et al. Barriers to adherence 
and hypertension control in a racially diverse representative sample of 
elderly primary care patients. Pharmacoepidemiol Drug Saf. 2009;18: 
672–681.
  14.  Dragomir A, Côté R, Roy L, et al. Impact of adherence to antihyperten-
sive agents on clinical outcomes and hospitalization costs. Med Care. 
2010;48:418–425.
  15.  Care Management International: Homepage. Available at: http://www.
caremanagementinternational.com/. Accessed November 14, 2010.
  16.  Robust J, Levy JM, Ingber MJ. Diagnosis based risk adjustment for 
Medicare prescription drug plan payments. Health Care Financ Rev. 
2007;28:15–30.
  17.  Bedell SE, Jabbour S, Goldberg S. Discrepancies in the use of 
medications. Their extent and predictors in outpatient practice. Arch 
Intern Med. 2000;160:2129–2134.
  18.  Jacob-Dunbar J, Stephens-Mortimer MK. Treatment adherence in 
chronic disease. J Clin Epidemiol. 2001;54:S57–S60.
  19.  Johnson MJ, Williams M, Marshall ES. Adherent and non adherent 
medication taking behavior in elderly hypertensive patients. Clin Nurs 
Res. 1999;83:318–335.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
205
Understanding barriers to medication adherence
Appendix 
Confirmation of presence of hypertension and use of target 
drug: Sampling of survey questions and responses:
1.  I see that recently you may have been prescribed [target 
drug], which is commonly used to lower blood pressure. 
Can you tell me if you are currently taking [target drug] 
for high blood pressure?
  Individuals were asked to respond by choosing one of 
these options: A Yes, still taking [target drug] for high 
blood pressure, B Yes, taking [target drug] but do not 
have high blood pressure or do not know if [target drug] 
is for high blood pressure, C No, not taking [target drug] 
but taking another drug for high blood pressure, or D No, 
not taking [target drug] anymore.
Dosing pattern
For those respondents who selected responses 1A, 1B, or 
1C, the following items were used to assess dosing pattern 
of the target drug:
2.  How many times per day do you take this medication?
  Individuals were asked to respond by choosing one of 
these options: A once, B twice, C three times, D other.
3.  At what time of the day do you take the medication?
  Individuals were asked to respond by choosing one 
or more of these options: A morning, B afternoon, 
C evening.
self-reported nonadherence
For those respondents who answered Question 2 and 
Question 3, the following items were used to determine 
  self-reported nonadherence to the target medication:
4.  Do you ever miss taking a dose of your [target drug] here 
or there?
  Individuals were asked to respond by choosing one of 
the following options: A yes or B no.
  Those who answered “no” to Question 4 were asked:
5.  “Have you ever picked up your prescription a couple of 
days after your pills ran out?
  Individuals were asked to respond by choosing one of 
the following options: A yes or B no.
Barriers to adherence
The following items were used to determine barriers to self-
reported nonadherence to the target medication for members 
who answered “yes” to Question 4:*
6.  Can you tell me a little bit about why you missed your 
dose [of the target drug] that time?
  Individuals were asked to respond freely (ie, in an 
open-ended format), after which the interviewer sum-
marized the respondent’s explanation and asked him or 
her to confirm that the dose was missed for up to three of 
the following reasons: A copay was too high, B drug had 
too many side effects, C drug did not work or there was 
no effect from taking the drug, D I just forgot, E I didn’t 
need the medication because my high blood pressure is 
under control without help, F I didn’t need the medica-
tion because I control my high blood pressure with other 
things (eg, exercise, diet), G I was too busy (other things 
more important), H I could not make it to the pharmacy, 
or I other reason.
*Follow-up questions to each of the specific barriers cited 
were also conducted but are not presented here.
Individuals who reported that they “just forgot” to take 
their target medication (6D) were asked:
7.  Can you tell me some of the reasons why you may forget 
to take your medication?
  Individuals were asked to respond by choosing up to three 
of the following options: A I am too busy sometimes, 
B I was traveling and forgot to pack the medication, 
C I was not able to perform my daily routine, D It just 
slipped my mind, E Random event happened and I could 
not take my medicine, or F other reason.
Means of medication purchase
For those who answered “no” to Question 5, the following 
item was used to determine where respondents purchased/
obtained their target medication:
8.  How do you most typically obtain your prescription for 
[target drug]?
  Please answer yes or no to the following: A Do you ever 
receive drug samples from your doctor?, B Does your phar-
macy insurance plan cover your prescriptions?, C Do you 
sometimes use another type of pharmacy insurance?, D Do 
you use a discount program offered by drug manufacturers?, 
E Do you ever buy your prescription through a special store 
offer, like the four dollar generic program at Walmart or 
Target stores?, or F None of the above.
self-reported aids to overcoming 
nonadherence
For members who responded to Question 7, the survey item 
below was used to determine self-reported aids to overcoming 
nonadherence to the target medication:
9.  What helps you remember to take your medications?Patient Preference and Adherence
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  Individuals were asked to respond by choosing one of the 
following options: A I have family or friends’ support, 
B I set a reminder, C It’s part of a daily routine, D I’m 
just good about remembering, or E other.
Use of mail-order pharmacy services
For those members who answered “yes” to Question 5, the 
following item was used to determine whether they would 
be interested in using mail-order pharmacies to obtain their 
target drug:
10. If you had an option to use the mail-order pharmacy, 
would you be interested?
  Individuals were asked to respond by answering A yes 
or B no.
Preferred method of receiving 
educational materials
At the end of the call, the following item was used to 
determine respondents’ preferred method of receiving 
  educational materials about blood pressure:
11. Finally, if your insurance plan were to provide you with 
educational material, which delivery method would you 
prefer?
  Individuals were asked to respond by choosing one 
or more of the following options: A Via regular mail 
(newsletters and letters), B via email, C via phone call 
with a live person, D via phone call through an automated 
voice system, or E none of the above – please don’t send 
me any information.